Allergy TherapeuticsLSE:AGY +0.30% Days Inventory is 170.78 as of Dec. 2025, which is 2% below its 10-year median of 174.66. The stock has 7 warning signs investors should review. Among 919 Drug Manufacturers companies, Allergy Therapeutics ranks worse than 54.84% on this metric.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Allergy Therapeutics's Inventory Turnover for the
six
months ended in Dec. 2025 was 1.07.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Allergy Therapeutics's Inventory-to-Revenue for the
six
months ended in Dec. 2025 was 0.38.
Allergy Therapeutics (LSE:AGY) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Allergy Therapeutics's Inventory Turnover for the
six
months ended in Dec. 2025 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Allergy Therapeutics's Inventory to Revenue for the
six
months ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Allergy Therapeutics Days Inventory Related Terms
Allergy Therapeutics Days Inventory Historical Data
* Premium members only.
The historical data trend for Allergy Therapeutics's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LSE:AGY vs ZTS, UTHR, VTRS: Days Inventory Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Allergy Therapeutics's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Allergy Therapeutics Days Inventory vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Allergy Therapeutics's Days Inventory distribution charts can be found below:
* The bar in red indicates where Allergy Therapeutics's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Allergy Therapeutics (LSE:AGY) has a Days Inventory of 170.78 as of Dec. 2025. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Allergy Therapeutics and its competitors. This is near median its historical median of 174.66. Over the past decade, Allergy Therapeutics' Days Inventory has ranged from 159.37 to 189.00. According to the industry distribution chart, Allergy Therapeutics ranks #504 out of 919 companies in the Drug Manufacturers industry, placing it in the top 54.8%.
Is Allergy Therapeutics' Days Inventory too high?
Allergy Therapeutics' current Days Inventory of 170.78 is near median its 10-year median of 174.66. Over the past 10 years, this metric has ranged from a low of 159.37 to a high of 189.00. The Drug Manufacturers industry median Days Inventory is 164.38. Allergy Therapeutics' value of 170.78 is 3.9% above this industry median. Based on the distribution chart, Allergy Therapeutics ranks #504 out of 919 companies in the Drug Manufacturers industry, which is below the industry midpoint.
How does Allergy Therapeutics' Days Inventory compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Allergy Therapeutics ranks #504 out of 919 companies for Days Inventory. This places Allergy Therapeutics in the lower half of its industry. The industry median Days Inventory is 164.38. Allergy Therapeutics' value of 170.78 is 3.9% above this benchmark. Historically, Allergy Therapeutics' own Days Inventory has ranged from 159.37 to 189.00 over the past decade. While the company's 10-year median is 174.66 vs. the industry median of 164.38, Allergy Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Drug Manufacturers company?
The median Days Inventory among Drug Manufacturers companies is 164.38, based on 919 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Allergy Therapeutics's current Days Inventory of 170.78 is 3.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Allergy Therapeutics and its competitors. For the Drug Manufacturers industry, the median Days Inventory is 164.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Allergy Therapeutics's current Days Inventory is 170.78, which is near median its own 10-year median of 174.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Allergy Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Allergy Therapeutics (LSE:AGY) is currently considered Significantly Overvalued. The stock's GF Value™ is £0.03, compared to a current price of £0.07 — trading 124% above its estimated fair value. The current Days Inventory is 170.78, which is near median its 10-year median of 174.66 and 3.9% above the Drug Manufacturers industry median of 164.38. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Allergy Therapeutics (LSE:AGY), the current Days Inventory is 170.78 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Allergy Therapeutics plc is an international biotechnology group focused on the diagnosis and treatment of allergic disorders through immunotherapies that target the underlying cause of disease. Its portfolio includes Pollinex, Pollinex Quattro, Acarovac, Tyrosine S/TU, Venomil, Oralvac and other allergy immunotherapy products, supported by R&D programmes such as Grass MATA MPL and VLP Peanut. The Group operates in a single class of business, being the manufacture and sale of allergy-related medicines, and maintains centralised manufacturing and research and development capabilities in the UK. Its geographical presence covers Central Europe (Germany, Austria, Switzerland and the Netherlands), Southern Europe (Spain and Italy) and the Rest of the World (including the UK).
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:AGY has been successfully added to your 